# Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

> **NCT04431635** · PHASE1 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Indolent Lymphoma

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Nivolumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04431635
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-15
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Loss of study funding
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04431635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04431635, "Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04431635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*